A biotechnology company in bankruptcy has brought malpractice claims against Nixon Peabody and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo.
In a suit filed Tuesday in the Eastern District, Neogenix Oncology Inc. said that at the direction of its former CFO, Peter Gordon, it paid commissions for sales of company stock, regardless of whether the “finders” were licensed to sell securities. The suit said the fee program violated securities laws because it compensated unlicensed finders based on their successful brokering the sale of stock.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
